Immuron (IMRN) Income towards Parent Company (2016 - 2024)
Immuron's (IMRN) quarterly Income towards Parent Company came in at -$1.6 million in Q4 2024, up 21.49% year-on-year from -$1.3 million in Q1 2024, and up 21.49% quarter-over-quarter from -$2.1 million in Q4 2023.
Immuron (IMRN) Income towards Parent Company (2016 - 2024) Analysis & Trends
Immuron's Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$1.6 million for Q4 2024.
- On a quarterly basis, Income towards Parent Company rose 21.49% year-over-year to -$1.6 million in Q4 2024; TTM through Sep 2025 was -$1.6 million, a 21.49% increase from a year earlier, with the FY2025 full-year figure at -$3.4 million, down 227575.8% from the prior year.
- Income towards Parent Company grew to -$1.6 million in Q4 2024 per IMRN's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$13260.2 in Q4 2021 and bottomed at -$2.1 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$795595.5 (2022), against an average of -$893766.8.
- Across the five-year window, Income towards Parent Company jumped 76.89% in 2021 and tumbled 2558.11% in 2022, its largest moves.
- Year by year, Income towards Parent Company stood at -$57387.7 in 2020, then soared by 76.89% to -$13260.2 in 2021, then tumbled by 2558.11% to -$352470.5 in 2022, then slumped by 488.19% to -$2.1 million in 2023, then advanced by 21.49% to -$1.6 million in 2024.
- Per Business Quant, the three latest IMRN Income towards Parent Company figures stand at -$1.6 million (Q4 2024), -$2.1 million (Q4 2023), and -$1.2 million (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Immuron | 255.19 Mn | 243.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.63 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -352,470.52 |
| Dec 31, 2021 | -13,260.17 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | -1.45 Mn |
| Dec 31, 2016 | -2.60 Mn |
| Jun 30, 2016 | -3.28 Mn |